Pyrazoline: A promising scaffold for the inhibition of Monoamine oxidase

Central Nervous System Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 195-206

  Mathew, Bijo ^a   Suresh, Jerad ^b   Anbazhagan, Sockalingam ^c   Mathew, Githa Elizabeth ^d  

^a Grace College of Pharmacy   (India)

^b MADRAS MEDICAL COLLEGE   (India)

^c Department of Pharmaceutical Chemistry   (India)

^d Grace College of Pharmacy   (India)

Author keywords

Anti depressant; Chirality; MAO A; MAO B; Molecular docking

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; MONOAMINE OXIDASE INHIBITOR; PYRAZOLINE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); ISOENZYME; PYRAZOLE DERIVATIVE;

ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHIRALITY; DRUG SELECTIVITY; ENZYME INHIBITOR INTERACTION; IC 50; MEDICINAL CHEMISTRY; MOLECULAR DOCKING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; HUMAN; METABOLISM;

ANIMALS; HUMANS; ISOENZYMES; MOLECULAR CONFORMATION; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899736062     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524914666140129122632     Document Type: Article

References (77)

1. Delay, J.; Laine, B.; Buisson, J.F. The action of isonicotinylhydrazide used in the treatment of depressive states. Ann. Med. Psychol., 1952, 110, 689-692.
2. Zeller, E.A.; Barsky, J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med., 1952, 81, 459-461.
3. Burger, A.; Yost, W.L. Arylcycloalkylamines. I.2-Phenylcyclo-propylamine. J. Am. Chem. Soc., 1948, 70, 2198-2201.
4. Maass, A.R.; Nimmo, M.J. A new inhibitor of serotonin metabolism. Nature, 1957, 184, 547-548.
5. Tedeschi, R.E.; Tedeschi, D.H.; Ames, P.L.; Cook, L.; Mattis, P.A.; Fellows, E.J. Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase. Proc. Soc. Exp. Biol. Med., 1959, 102, 380-381.
6. Siddiqui, N.; Bawa, S.; Ali, R.; Akhtar, M.J.; Azad, B.; Kumar, R. Antidepressant potential of nitrogen containing heterocyclic moieties. An updated review. J. Pharm. Bioall. Sci., 2011, 3, 194-212.
7. Abdelhafez, O.M.; Amin, K.M.; Ali, H.A.; Abdalla, M.M.; Batran, B.Z. Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized Coumarin derivatives. Neurochem. Int., 2013, 62, 198-209.
8. Yáñez, M.; Padín, J.F.; Arranz-Tagarro, J.A.; Camiña, M.; Laguna, R. History and therapeutic use of MAO-A inhibitors: A historical perspective of MAO-A inhibitors as antidepressant drug. Curr. Top. Med. Chem., 2012, 12, 2275-2282.
9. Mathew, B.; Suresh, J.; Anbazhagan, S. Development of novel (1-H) benzimidazole bearing pyrimidine-trione based MAO-A inhibitors: Synthesis, docking studies and antidepressant activity. J. Saud. Chem. Soc. 2012, http://dx.doi.org/10.1016/j.jscs.2012.09.015.
10. Johnston, J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 1968, 17, 30-36.
11. Saura, M.J.; Kettler, R.; Da Prada M.; Richards, J.G. Molecular neuroanatomy of MAO-A and MAO-B. J. Neural. Transm. Suppl., 1990, 32, 49-53.
12. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 12684-12689.
13. Singer, T.P. Perspectives in MAO: past, present and future. A review. J. Neural. Transm. Suppl., 1987, 23, 1-23.
14. O'Carroll A.M.; Fowler C.J.; Phillips J.P.; Tobbia, I.; Tipton, K.F. The deamination of dopamine by human brain monoamine oxidase-specificity for the 2 enzymes forms in 7 brain regions. Naunyn Scheiedeberges Arch. Pharmacol., 1983, 332, 198-202.
15. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human oxidase-B, a drug target for the treatment neurological disorders. Nat. Struct. Mol. Biol., 2002, 9, 22-26.
16. Cesura, A.M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug. Res., 1992, 38, 171-297.
17. Pacher, P.; Kecskemeti, V. Trends in the development of new antidepressants. Is there a light at the end of tunnel? Curr. Med. Chem., 2004, 11, 925-943.
18. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO-inhibitors: safety and future. Neurotoxicology, 2004, 25, 215-221.
19. Carreiras, M.C.; Marco, J.L. Recent approaches to novel anti-Alzheimer's therapy. Curr. Pharm. Des., 2004, 10, 3167-3175.
20. Fernandez, H.H.; Chen, J.J. Monoamine oxidase-B inhibition in the Parkinson's disease. Pharmacotherapy, 2007, 27, 174S-185S.
21. Woulters, J. Structural aspects of Monoamine oxidase and its reversible inhibition. Current. Med. Chem., 1998, 5, 137-162.
22. Veselovsky, A.A.; Ivanov, A.S.; Medvedv, A.E. Computer modelling and visualization of active site of Monoamine oxidase. Neurotoxicology, 2004, 25, 37-46.
23. Naoia, M.; Maruyamab, W.; Inaba-Hasegawa, K. Type A and B Monoamine oxidase in age-related neurodegenerative disorders: Their distinct roles in neuronal death and survival. Curr. Top. Med. Chem., 2012, 12, 2177-2188.
24. Kumar, S.; Bawa, S.; Drabu, S.; Kumar, R.; Gupta, H. Biological activities of pyrazoline derivatives--a recent development. Recent. Pat. Antiinfect. Drug. Discov., 2009, 4, 154-163.
25. Wiley, R.H., Behr, L.C.; Fusco, R.; Jarboe, C.H. The chemistry of heterocyclic compounds: Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings. John Wiley & Sons, Ltd: New York, 1967.
26. Parmar, S.S.; Pandey, B.R.; Dwivedi, C.; Harbison, R.D. Anticonvulsant activity and monoamine oxidase inhibitory properties of 1, 3, 5-trisubstituted pyrazolines. J. Pharm. Sci., 1974, 63, 1152-1155.
27. Soni, N.; Pande, K.; Kalsi, R.; Kupta, K.T.; Parmar, S.S.; Barthwal, J. Inhibition of rat brain monoamine oxidase and succinic dehydrogenase by anticonvulsant pyrazolines. Res. Commun. Chem. Pathol. Pharmacol., 1987, 56, 129-132.
28. Karthikeyan, M.S.; Holla, B.S.; Kumari, N.S. Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines. Eur. J. Med. Chem., 2007, 42, 30-36.
29. Ozdemir, A.; Turan-Zitouni, G.; Kaplancikli, Z.A.; Revial, G.; Guven, K. Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives. Eur. J. Med. Chem., 2007, 42, 403-409.
30. Bawa, S.; Kumar, S.; Drabu, S.; Panda, B.P.; Kumar, R. Synthesis and antimicrobial activity of 2-chloroquinoline incorporated pyrazoline derivatives. J. Pharm. Bioall. Sci., 2009, 1, 32-36.
31. Ozdemir, A.; Turan-Zitouni, G.; Kaplancikli, Z.A. Novel analogues of 2-pyrazoline: synthesis, characterization, and antimycobacterial evaluation. Turk. J. Chem., 2008, 32, 529-538.
32. Ali, M.A.; Shaharyar, M. Discovery of novel phenoxyacetic acid derivatives as antimycobacterial agents. Bioor. Med. Chem., 2007, 15, 1896-1902.
33. Kumar P.M.; Kumar, R.A.; Ravi, T.K. Synthesis and antitubercular activity studies of substituted pyrazolines. Indian J. Pharm. Sci., 2005, 74, 755-757.
34. Aboul-Enein, M.N.; El-Azzouny, A.A.; Attia, M.I.; Maklad, Y.A.; Amin, K.M.; Abdel-Rehim, M.; El-Behairy, M.F. Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur. J. Med. Chem., 2012, 47, 360-369.
35. Chandra, T.; Garg, N.; Lata, S.; Saxena, K.K.; Kumar, A. Synthesis of substituted acridinyl pyrazoline derivatives and their evaluation for anti-inflammatory activity. Eur. J. Med. Chem., 2010, 45, 1772-1776.
36. Congiu, C.; Onnis, V.; Vesci, L.; Castorina, M.; Pisano, C. Synthesis and in vitro antitumor activity of new 4, 5-dihydropyrazole derivatives. Bioorg. Med. Chem., 2010, 18, 6238-6248.
37. Babu, V.H.; Sridevi, C.H.; Joseph, A.; Srinivasan, K.K. Synthesis and biological evaluation of some novel pyrazolines. Indian. J. Pharm. Sci., 2007, 69, 470-479.
38. Ucar, G.; Gokhanb, N.; Yesilada, A. Bilgin, A. A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci. Lett., 2005, 382, 327-331.
39. Marella, A.; Ali, M.R.; Alam, M.T.; Saha, R.; Tanwar, O.; Akhter, M.; Shaquiquzzaman, M.; Alam, M.M. Pyrazolines: a biological review. Mini. Rev. Med. Chem., 2013, 13, 921-931.
40. Palaska, E.; Aytemir, M.; Uzbay, I.T.; Erol, D. Synthesis and antidepressant activities of some 3, 5-diphenyl-2-pyrazolines. Eur. J. Med. Chem., 2001, 36, 539-543.
41. Prasad, Y.R.; Rao, A.L.; Prasoona, L.; Murali, K.; Kumar, P.R. Synthesis and antidepressant activity of some1,3,5-triphenyl-2-pyrazolines and 3-(2-hydroxy naphthalen-1-yl)-1,5-diphenyl-2-pyrazolines. Bioorg. Med. Chem. Lett., 2005, 15, 5030-5034.
42. Ozdemir, Z.; Kandilci, H.B.; Gumusel, B.; Calis, U.; Bilgin, A.A. Synthesis and studies on anti-depressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur. J. Med. Chem., 2007, 42, 373-379.
43. Kaplancikli, Z.A.; Özdemir, A.; Turan-Zitouni, G.; Altintop, M.D.; Can, O.D. New pyrazoline derivatives and their antidepressant activity. Eur. J. Med. Chem., 2010, 45, 4383-4387.
44. Gok, S.; Demet, M.M.; Ozdemir, A.; Turan-Zitouni, G. Evaluation of antidepressant-like effect of 2-pyrazoline derivatives. Med. Chem. Res., 2010, 19, 94-101.
45. Secci, D.; Carradori, S.; Bolascoa, A.; Bizzarria, B.; D'Ascenzioa, M.; Maccioni, E. Discovery and optimization of pyrazoline derivatives as promising Monoamine oxidase inhibitors. Curr. Top. Med. Chem., 2012, 12, 2240-2257.
46. Manna, F.; Chimenti, F.; Bolasco, A.; Bizzarri, B.; Befani, O.; Pietrangeli, P.; Mondovi, B.; Turini, P. Inhibitory effect of 1, 3, 5-triphenyl-4, 5-dihydro-(1H)-pyrazole derivatives on activity of amine oxidases. J. Enzyme Inhib., 1998, 13, 207-216.
47. Manna, F.; Chimenti, F.; Bolasco, A.; Secci, D.; Bizzarri, B.; Befani, O.; Turini, P.; Mondovi, B.; Alcaroc, S.; Tafi, A. Inhibition of Amine oxidases activity by 1-Acetyl-3,5-diphenyl-4,5-dihydro-1(H)-pyrazole derivatives. Bioorg. Med. Chem. Lett., 2002, 12, 3629-3633.
48. Gokhan, N.; Yesilada, A.; Ucüar, G.; Erol, K.; Bilgin, A.A. 1-Nsubstituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and evaluation as MAO inhibitors. Arch. Pharm. (Weinheim, Ger.), 2003, 336, 362-371.
49. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V; Mondovi, B.; Cirilli, R.; Torre, F.L. Synthesis and selective inhibitory activity of 1-Acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against Monoamine oxidase. J. Med. Chem., 2004, 47, 2071-2074.
50. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaroc, S.; Ortuso, F.; Cirilli, R.; Torre, F.L.; Cardia, M.C.; Distinto, S. Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives. J. Med. Chem., 2005, 48, 7133-7122.
51. Takasaki, W.; Yamamura, M.; Nozaki, A.; Nitanai, T.; Sasahara, K.; Itoh, K.; Tanaka, Y. Stereoselctive pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species dependent drug-metabolizing enzymes. Chirality, 2005, 17, 135-141.
52. Walter, W.; Voss, J. The Chemistry of Amides. Zabicky, J., Ed.; Wiley and Sons London, Chapter 8, pp 385-415, 1970.
53. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaroc, S.; Ortuso, F. Synthesis and molecular modelling of novel substituted -4-5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors. Chem. Biol. Drug. Des., 2006, 67, 206-214.
54. Kelekci, N.G.; Yabanoglu, S, Kupeli, E.; Salgin, U.; Ozen, O.; Ucar, G.; Yesilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A. A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and anti-inflammatory analgesics. Bioorg. Med. Chem. Lett., 2007, 15, 5775-5786.
55. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Rossi, F.; Turini, P.; Ortuso, F.; Alcaro Cardia, M.C. Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4, 5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2008, 43, 2262-2267.
56. Jayaprakash, V.; Sinha, B.N.; Ucar, G.; Ercan, A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6362-6368.
57. Kelekci, N.G.; Koyunoglu, S.; Yabanoglu, S.; Yelekci, K.; Ozgen, O.; Ucar, G.; Erol, K.; Kendi, E.; Yesiladan, A. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation and structural determinants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem., 2009, 17, 675-689.
58. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3, 5-di(hetero)aryl- 4, 5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2010, 45, 800-804.
59. Shaoo, A.; Yabanoglu, S.; Sinha, B.N.; Ucar, G.; Basu, A.; Jayaprakash, V. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2010, 20, 132-136.
60. Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yanez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D. Synthesis of new 3-aryl-4,5dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur. J. Med. Chem., 2010, 45, 4490-4498.
61. Karuppasamy, M.; Mahapatra, S.; Yabanoglu, S.; Ucar G.; Sinha, B.N.; Basu, A.; Mishra, N.; Sharon, A.; Kulandaivelu, U.; Jayaprakash, V. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem., 2010, 18, 1875-1881.
62. Fioravanti, R.; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yanez, M.; Vital, A.; Ortuso, F.; Alcaro, S. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6479-6482.
63. Mishra, N.; Sasmal, D. Development of selective and reversible pyrazoline based MAO-B inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 1969-1973.
64. Jagrat, M.; Behera, J.; Yabanoglu, S.; Ercan, A.; Ucar, G.; Sinha, B.N.; Sankaran, V.; Basu, A.; Jayaprakash, V. Pyrazoline based MAO- inhibitors: Synthesis, biological evaluation and SAR studies. Bioorg. Med. Chem. Lett., 2011, 21, 4296-4300.
65. Senturk, K.; Tan, O.U.; Ciftci, S.Y.; Ucar, G.; Palaska, E. Synthesis and evaluation of human Monoamine oxidase inhibitory activities of some 3,5-Diaryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives. Arch. Pharm. Chem. Life Sci., 2012, 345, 695-702.
66. Fioravanti, R.; Desideri, N.; Biava, M.; Monaco, L.P.; Grammatica, L.; Yáñez,M.; Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles. Bioorg. Med. Chem. Lett., 2013, 23, 5128-5130.
67. Nayak, B.V.; Ciftci-Yabanoglu, S.; Singh, S.; Jagrat, M.; Sinha, B.N.; Ucar, G.; Jayaprakash, V. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur. J. Med. Chem., 2013, 69, 762-767.
68. Salgin-Goksen, U.; Yabanoglu-Ciftci, S.; Ercan, A.; Yelekci, K.; Ucar, G.; Gokhan-Kelekci, N. Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives. J. Neural. Transm., 2013, 120, 863-873.
69. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcarod, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3d-qsar of 1,3,5-trisubstituted-4,5-dihydro-(1h)-pyrazole derivatives as potent and highly selective monoamine oxidase a inhibitors. Curr. Med. Chem., 2006, 13, 1411-1428.
70. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Befani, O.; Turini, P.; Ortuso, F.; Alcaro, S. Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3, 5-diaryl pyrazole inhibitors. J. Med. Chem., 2007, 50, 425-428.
71. Ferino, G.; Vilar, S.; Matos, M.J.; Uriarte, E.; Cadoni, E. Monoamine Oxidase Inhibitors: Ten Years of Docking Studies. Curr. Top. Med.Chem., 2012, 12, 2145-2162.
72. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidase A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
73. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem., 2007, 50, 5848-5852.
74. Rahman, T.; Rahmatullah, M. Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg. Med. Chem. Lett., 2010, 20, 537-540.
75. Son, S.Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/ inhibitors. Proc. Natl. Acad. Sci. USA, 2008, 105, 5739-5744.
76. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. USA, 2003, 100, 9750-9755.
77. Cirilli, R.; Ferretti, R.; Gallinella, B.; Turchetto, L.; Bolasco, A.; Secci, D.; Chimenti, P.; Pierini, M.; Fares, V.; Befani, O.; La Torre, F. Enantiomers of C-5-chiral 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives: analytical and semi-preparative HPLC separation, chiroptical properties, absolute configuration, and inhibitory activity against monoamine oxidase. Chirality, 2004, 16, 625-636.